Instil Bio Inc

TIL | $10.21 -6.29% -6.71% 27K

(0.0% 1d) (-12.6% 1m) (1575.4% 1y) (-1.5% 2d) (-0.2% 3d) (0.1% 7d) (104.57% volume)
Earnings Calendar: 2023-11-13
Market Cap: $ 66,404,952
https://instilbio.com
Sec Filling | Patents | 412 employees

(US) Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous TIL therapies for the treatment of patients with cancer.

cancer t-cell treatment ceiling

add to watch list Paper trade email alert is off

Tscan Therapeutics Inc

TCRX | $7.66 -1.16% -1.17% 120K

Professional, Scientific, and T...

(0.0% 1d) (14.1% 1m) (253.9% 1y) (-0.6% 2d) (7.2% 3d) (5.6% 7d) (-23.36% volume)
Earnings Calendar: 2024-03-06
Market Cap: $ 334,191,621
https://www.tscan.com
Sec Filling | Patents | 61 employees

TScan is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company’s lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. The company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

treatment cancer leukemia t-cell

add to watch list Paper trade email alert is off

Unicycive Therapeutics Inc

UNCY | $1.12 -8.2% -8.93% 1.1M

Professional, Scientific, and T...

(0.0% 1d) (-15.3% 1m) (-31.1% 1y) (-2.4% 2d) (-6.2% 3d) (-11.9% 7d) (153.13% volume)
Earnings Calendar: 2022-11-10
Market Cap: $ 38,927,208
https://unicycive.com
Sec Filling | Patents | 2021 employees

Unicycive is a biotechnology company developing novel treatment for kidney diseases. Unicycive's lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. UNI-494 is a patent protected new chemical entity in late preclinical development for the treatment of acute kidney injury.

treatment kidney

add to watch list Paper trade email alert is off

Finch Therapeutics Group Inc

FNCH | $2.285 -2.77% -2.84% 20K

Professional, Scientific, and T...

(0.0% 1d) (-18.8% 1m) (-82.8% 1y) (-13.6% 2d) (-17.1% 3d) (-9.0% 7d) (59.64% volume)
Earnings Calendar: 2023-03-30
Market Cap: $ 3,669,168
https://finchtherapeutics.com
Sec Filling | Patents | n/a employees

Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs. With the capabilities to develop both complete and targeted microbiome therapeutics, Finch is advancing a rich pipeline of candidates designed to address a wide range of unmet medical needs. Finch’s lead candidate, CP101, is in late-stage clinical development for the prevention of recurrent C. difficile infection (CDI), and has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration. In June 2020, Finch announced that CP101 met its primary efficacy endpoint in PRISM3, the first of two pivotal trials to support the development of CP101 for the prevention of recurrent CDI. Finch plans to initiate a Phase 3 trial, referred to as PRISM4, as its second pivotal trial of CP101 for recurrent CDI. Finch is also developing CP101 for the treatment of chronic hepatitis B virus, and FIN-211 for the treatment of the gastrointestinal and behavioral symptoms of autism spectrum disorder. In partnership with Takeda, Finch is advancing FIN-524 and FIN-525 for the treatment of ulcerative colitis and Crohn’s disease, respectively.

hepatitis gastrointestinal treatment injection

add to watch list Paper trade email alert is off

Acumen Pharmaceuticals Inc

ABOS | $3.545 -5.21% -5.5% 210K

Professional, Scientific, and T...

(0.0% 1d) (-8.6% 1m) (0.0% 1y) (-3.9% 2d) (0.8% 3d) (-3.9% 7d) (16.74% volume)
Earnings Calendar: 2024-03-25
Market Cap: $ 212,982,813
https://www.acumenpharm.com
Sec Filling | Patents | 2021 employees

Acumen is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target amyloid-beta oligomers, (AβOs), which Acumen believes to be a key underlying cause of Alzheimer’s disease, or AD. Acumen is currently focused on advancing a targeted immunotherapy drug candidate, ACU193, to establish proof of mechanism in early AD patients. Acumen initiated its Phase 1 clinical trial of ACU193 in the second quarter of 2021 with the objective to evaluate its safety and tolerability and explore its pharmacokinetics and target engagement. This trial is currently enrolling patients with mild cognitive impairment and mild dementia due to AD. ACU193 Phase 1 data intended to evaluate safety and tolerability and demonstrate clinical proof of mechanism are expected by year end 2022.

alzheimer alzheimer’s

add to watch list Paper trade email alert is off

Alzamend Neuro Inc

ALZN | $0.7707 -9.33% -10.29% 110K

Professional, Scientific, and T...

(0.0% 1d) (-12.4% 1m) (44.7% 1y) (-4.8% 2d) (-3.4% 3d) (-3.7% 7d) (254.68% volume)
Earnings Calendar: 2024-03-14
Market Cap: $ 5,292,278
https://alzamend.com/
Sec Filling | Patents | 3 employees

(United States) Alzamend Neuro is a preclinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer’s disease. With its product candidates, the company aims to bring treatments or cures to market at a reasonable cost as quickly as possible. Its current pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s. Both of its product candidates are licensed from the University of South Florida Research Foundation, Inc. pursuant to royalty-bearing exclusive worldwide licenses.

treatment msa vaccine t-cell lithium alzheimer neurodegenerative alzheimer’s

add to watch list Paper trade email alert is off

BriaCell Therapeutics Corp.

BCTX | $2.37 -4.05% -4.22% 36K

Professional, Scientific, and T...

(0.0% 1d) (-7.4% 1m) (-61.7% 1y) (0.0% 2d) (0.0% 3d) (-2.1% 7d) (NaN% volume)
Earnings Calendar:
Market Cap: $ 37,876,691
https://www.briacell.com
Sec Filling | Patents | 2022 employees

BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer.

cancer

add to watch list Paper trade email alert is off